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Summary
Injection drug users uninfected by hepatitis C virus (HCV) despite likely repeated 
exposure through high- risk behaviour are well documented. Factors preventing infec-
tion in these individuals are incompletely understood. Here, we looked for anti- HCV- 
envelope antibody responses in a cohort of repeatedly exposed but uninfected 
subjects. Forty- two hepatitis C diagnostic antibody- and RNA- negative injection drug 
users at high risk of exposure were studied and findings compared to healthy controls 
and cases with chronic HCV infection. Purified IgGs from sera were tested by ELISA 
for binding to genotype 1a and 3a envelope glycoproteins E1E2 with further testing 
for IgG and IgM reactivity against soluble E2. Virus- neutralizing activity was assessed 
using an HCV pseudoparticle system. Uninfected subjects demonstrated significantly 
greater IgG and IgM reactivities to envelope glycoproteins than healthy controls with 
IgG from 6 individuals additionally showing significant neutralization. This study is the 
first to describe humoral immunological responses targeting the HCV envelope, impor-
tant for viral neutralization, in exposed uninfected individuals. A subset of these cases 
also had evidence of viral neutralization via anti- envelope antibodies. In addition to 
confirming viral exposure, the presence of specific anti- envelope antibodies may be a 
factor that helps these individuals resist HCV infection.
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Hepatitis C virus (HCV) is a major cause of liver morbidity and mor-
tality worldwide.1 Approximately 75% of infected individuals pro-
ceed to chronic infection.2 In developed countries, the major route 
of transmission remains the use of injection drugs and sharing of 
related paraphernalia by injection drug users (IDUs).3 Symptomatic 
acute infection is rare, and HCV has the potential to spread unde-
tected within these populations. While effective antiviral medication 
is now available,4 treatment remains costly and ineffectively imple-
mented with the prevalence of HCV in IDUs rising in England.5 It 
is clear that global eradication of HCV will not be possible unless 
robust preventative strategies are also developed.6 Studying individ-
uals who resist infection can help inform prevention strategies and 
vaccine design.
In natural infection, successful clearance of HCV infection has 
been associated with the activation of elements of both the adap-
tive and the innate immune system (e.g. HCV- specific B and T cell, 
NK cell, dendritic cell and interferon responses7–10). There is grow-
ing evidence that a robust antibody response targeting HCV virion *Both authors contributed equally to the work and are joint first authors.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
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envelope glycoproteins (E1 and E2) responsible for virus entry into 
host cells can contribute significantly to viral clearance in acute 
infection.11–16 Rapid onset of anti- HCV envelope antibodies17 capa-
ble of neutralizing diverse strains of HCV is associated with acute 
clearance. Furthermore, broadly neutralizing antibodies may contrib-
ute to resolution of infection even once HCV has become estab-
lished.11,18 In the search for a prophylactic vaccine, it is especially 
relevant to study individuals who appear to have natural resistance 
to HCV infection. Individuals who regularly inject drugs and share 
injecting equipment are at very high risk of HCV exposure with 
seroprevalence rates of up to 90% reported in long- term users. 
Resistance to HCV infection is increasingly well documented in IDUs 
who remain uninfected despite a long history of unsafe injection 
practices.19 Individuals at high risk of exposure with no evidence of 
past or current infection have been termed exposed but uninfected 
(EU).
EU cohorts are immunologically distinct from both healthy controls 
and those who spontaneously clear HCV infection (see Table 1).20–22 
Up to 60% of EU individuals display HCV- specific adaptive T- cell 
responses. Furthermore, they display enhanced NK cell, IL6/IL8 and 
TNF- α activity compared to HCV- infected IDUs.23,24 They are also 
genetically distinct from spontaneous resolvers and those with chron-
ic HCV9 with the combination of KIR2DL3, HLA- C1 over represented 
in both the EU and spontaneous resolver groups while the prevalence 
of the IL28B polymorphism is similar in EU to chronically infected 
cohorts.22,24–26
While this EU cohort is defined by the lack of antibody response 
to HCV core and nonstructural proteins in a diagnostic assay, the role 
that anti- envelope neutralizing antibodies might play in their protec-
tion from infection has not yet been explored. Given the upregulation 
of neutralizing antibodies in those who acutely clear HCV infection 
on multiple exposures, it is possible that such antibodies may have 
a significant protective effect in the IDU EU population.12 Therefore, 
we aimed to determine the presence of functional anti- HCV envelope 
antibody responses in a cohort of IDUs who remain uninfected despite 
their high risk of repeated exposure to HCV.
2  | MATERIALS­AND­METHODS
2.1 | The­EU­and­control­cohorts
A cohort of current IDU not known to have HCV infection or other 
blood borne viruses was recruited between 2003 and 2014 from a 
variety of locations in Plymouth, UK, as previously described.21,22 All 
individuals completed a confidential structured questionnaire to col-
lect demographic data and a detailed injecting history. This included 
age at first injection, duration of injecting behaviour, frequency of 
injecting episodes, current injecting behaviour, frequency of shar-
ing intravenous paraphernalia (needles, syringes, filters, spoons and 
water), frequency of sharing with a contact known to have HCV infec-
tion and risk of non- IDU HCV exposure. For this study, we included 
only those judged to be at substantial risk of HCV exposure based on 
a >1 year history of injecting drug use and regular sharing of needles 
and related paraphernalia. All individuals had serum and whole blood 
samples drawn for laboratory analysis and clinical details entered in 
respective databases. Where possible, follow- up clinical information 
and clinical samples from recruited individuals were obtained.
The exposed group was screened for the evidence of current or 
previous HCV infection using diagnostic tests for antibodies to core 
and nonstructural proteins (third- generation ELISA by Abbot IMx) and 
HCV RNA by qualitative PCR (Amplicor, Roche Diagnostics). Those 
individuals negative on both tests were termed exposed uninfected 
(EU) and were included in the study. Two individuals who were found 
to have developed HCV infection on subsequent testing were exclud-
ed. In addition, we separately recruited positive and negative control 
cohorts of individuals with chronic HCV infection (CHCV) and non- 
IDU healthy controls (HC) with no liver disease or history of HCV 
infection, respectively. The full details of these cohorts have been 
described elsewhere.27
Study protocols conformed to the ethical guidelines of the 1975 
Declaration of Helsinki as reflected in a priori approval by regional 
ethical committees. Informed written consent was obtained from each 
subject prior to entry in the study.
TABLE  1  Immunological characteristics of exposed uninfected individuals
Immunological­Component Functional­Outcome Comparator­Group Reference
IL28B CC allele (rs12979860) No difference compared to chronically infected individuals. 
Reduced frequency compared to spontaneous resolvers
Spontaneous resolvers and 
chronically infected individuals
[9]
KIR2DL3 genotype Increased frequency of KIR2DL3:HLA- C1 homozygosity Chronically infected individuals [26]
No difference in frequency of KIR2DL3:HLA- C1 
homozygosity
Pre- infection samples from IDUs 
with subsequent seroconversion
[25]
IL12B CC allele (rs3213113) Increased frequency compared to healthy controls Healthy controls [22]
Serum cytokine levels Elevated IL6, IL8 and TNF- α Healthy controls, spontaneous 
resolvers and chronically infected 
individuals
[24]
HCV- specific T cells Evidence of IFN- γ production and T- cell proliferation Healthy controls and chronically 
infected individuals
[21,41]
Natural Killer Cells Enhanced IL- 2- mediated cytotoxicity. Increased NKp30 
expression
Pre- infection samples from IDUs 
with subsequent seroconversion
[23]




Statistical analysis was conducted using GraphPad Prism 6 Software 




As genotypes 1 (gt 1) and 3 (gt 3) account for the vast majority of HCV 
infections in the UK, envelope glycoprotein sequences from a stand-
ard HCV gt 1a and a UK derived gt 3 strain were used. HCV pseudo-
particles bearing envelope proteins from gt 1a (strain H77c, accession 
number AF011751.1) and gt 3a (sequence UKN3a1.28 F4/2- 35; 
closely related to accession number AY734984.1) were generated in 
HEK- 293T cells as described previously.28 Further details are avail-
able in Supplementary Methods. Following harvesting of pseudopar-
ticles, cells were lysed in 1 mL of lysis buffer and centrifuged and the 
supernatant used for E1E2 ELISA assays as described below.
2.4 | GNA­capture­E1E2­ELISA
IgG was purified from EU, CHCV and HC samples using Protein G 
IgG- specific spin columns (Thermo Scientific, UK; see Supplementary 
Methods) including 3 wash steps prior to elution ensuring removal of 
nonspecific serum factors that may interfere with the assay. Purified 
IgG was tested in an ELISA assay to detect antibodies to the E1 and E2 
glycoproteins contained in the HEK- 293T lysate supernatant. These 
ELISAs were performed as described previously with further detail 
in Supplementary Methods.29 Absorbance readings were normal-
ized to a multiple of the mean of the HC readings. Significant binding 
by ELISA was determined as absorbance values ≥2 times HC mean. 
Reactivity to both gt 1a and gt 3a E1E2 was tested.
2.5 | Soluble­gt­1a­E2­binding­ELISAs:­IgG­and­IgM
As IgM is difficult to purify, diluted serum was used to detect bind-
ing of IgG and IgM to purified HCV soluble gt 1a E2 (sE2). EU and 
control serum samples were diluted 1:50 in PBSTM and tested for 
binding to sE2 by ELISA. Absorbance readings were normalized to 
healthy control mean and analysed as above with further detail in the 
Supplementary Methods.
2.6 | Pseudoparticle­neutralization­assays
In the subset of EU individuals displaying significantly elevated E1E2 
binding compared to HC on ELISA, pseudoparticle (pp) neutralization 
assays were conducted as previously described.30 Briefly, purified sub-
ject IgG was added to 40 μL of HCVpp- containing medium prepared 
as above. Purified IgG was added at a concentration of 400 μg mL−1 
for screening of the EU cohort, for some individuals where serum 
was scarce, this was reduced to 200 μg mL−1. The mouse monoclonal 
anti- E2 antibody AP3331 and HC IgG were included as positive and 
negative controls, respectively. After incubation for 1 hour, the IgG- 
HCVpp mixture was added to a 96- well plate preseeded with Huh- 7 
cells. Following incubation for 3 hour, the inoculum was replaced with 
fresh medium, and after a further 72- hour incubation, luciferase activ-
ity in infected cells was detected as a marker of HCVpp infectivity 
using the Bright- Glo Luciferase kit (Promega, UK). Virus neutralization 
was defined as 50% reduction in pseudoparticle infectivity as meas-
ured in relative light units (RLU) using a Chameleon II plate reader. 
Ability to neutralize both gt 1a and gt 3 was tested. For those samples 
with apparent neutralizing activity, further neutralization assays were 
conducted using serial dilutions of subject IgG.
2.7 | E2­competition­ELISA
For EUs with neutralizing activity and sufficient IgG available, com-
petition ELISAs were performed using a panel of well- characterized 
monoclonal antibodies targeting known CD81- binding epitopes 
(Table S1). CHCV samples with known neutralizing activity were used 
as positive controls.
Purified IgG was incubated on E2- coated Immulon II plates at a 
concentration of 200 μg mL−1 in PBSTM. Subsequently, biotinylated 
antibodies to known conformational epitopes were added to these 
wells in addition to control wells with no EU IgG. Streptavidin- HRP 
was added and binding measured as previously. The reduction in rel-
ative binding of each biotinylated antibody (calculated as percentage 
reduction in absorbance) on addition of EU IgG compared to control 
was determined. PBSTM and neutralizing IgG from the CHCV cohort 
were used as negative and positive controls, respectively.
3  | RESULTS
3.1 | Clinical­cohorts
Forty- two EU subjects, 8 gt 1 chronically infected patients (CHCV) and 
8 healthy controls (HC) were studied. By definition, all EU cases con-
sistently tested negative for HCV RNA and anti- HCV antibodies using 
standard diagnostic tests as described. In 5 EU individuals, serial sam-
ples were tested. Demographics of the cohorts are detailed in Table 2.
3.2 | Reactivity­of­IgG­to­HCV­envelope
The median absorbance readings for the HCV gt 1a E1E2 capture 
ELISA were significantly higher in the EU cohort than in the HC 
group (P=.038) (Fig. 1a). While there was a trend towards overall 
higher absorbance readings against gt 3a E1E2 in the EU group than 
in controls, this did not reach significance (P=.067, Fig. 1b). However, 
three samples showed levels of binding to gt 3a lysate comparable to 
 chronically infected controls.
3.3 | HCV­exposure­risk­and­E1E2­reactivity
EU IgG absorbance levels to gt 1a E1E2 and gt 3a E1E2 were analysed 
for association with reported injection behaviour with a significant 
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correlation between IgG reactivity against gt 1a E1E2 and greater life-
time injecting episodes (Spearman R=.38, P=.02, Fig. 1c), although this 
association was not seen with gt 3a reactivity (Fig. 1d).
3.4 | IgG­and­IgM­sE2­ELISA
To eliminate reactivity against HEK antigens and medium compo-
nents, diluted serum samples from all individuals were tested for IgG 
reactivity to gt 1a sE2. For two of the subjects, serum from 2 separate 
time points was tested. There was significantly higher absorbance of 
IgG from EU to sE2 than HC (P<.01, Fig. 2a). Serum was also tested 
for IgM binding to sE2. The EU cohort showed significantly higher 
quantities of IgM binding to sE2 than the HC group (P=.001 Wilcoxon 
rank sum, Fig. 2b) with several individuals displaying levels compara-
ble to the CHCV group (data not shown).
3.5 | Positivity­across­multiple­assays
We set a cut- off of absorbance ≥2 times the HC mean value as indicat-
ing a significantly positive result. Overall, 20 of 42 (47%) EU showed 
evidence of IgG reactivity to HCV envelope E1E2 proteins on either the 
GNA capture ELISA or IgG gt 1a purified soluble E2 (sE2) binding ELISA 
using this cut- off (Table S2). Four of the 7 EUs with ≥2 times the HC 
mean binding to gt 1a E1E2 lysate also had significant binding to sE2 
F IGURE  1 EU individuals show 
elevated IgG reactivity to HCV envelope 
proteins which correlates with lifetime 
risk of exposure. (a+b) Purified IgGs were 
tested for their ability to bind HEK- 293T- 
expressed E1E2 in a (a) GNA capture gt 
1a and (b) GNA capture gt 3a ELISAs. 
For those individuals where serum from 
multiple time points was available, each 
time point was tested individually, but 
only one value for each individual (i.e. the 
first sample taken) is plotted. Statistical 
differences between the groups were 
calculated using the Wilcoxon rank sum 
test (*P<.05). (c+d) Correlation between 
IgG reactivity to either gt 1a (c) or gt 3a 
(d) and total number of lifetime injecting 
episodes (duration of reported injection 
drug use multiplied by the frequency of 
reported injection drug use) was plotted 
for 37 EU (injection data not available for 
the remaining 5)







Mean age at sampling 34±8.3 52±6.3 47±18.2
Ethnicity (% Caucasian) 100 100 100
Sex (% Male) 89 63 50
Current IDU (%) 100 – 0
Mean age at commencing IDU (years±SD) 21.8±5.2 ND N/A
Mean lifetime injecting episodes (range) 4128 (52–21 900) ND N/A
Duration of IDU (years±SD) 7.6±4.3 ND N/A
Sharing needles/syringes (%) 72 ND N/A
Sharing any injection equipment (%) 100 ND N/A
Sharing with IDU known to suffer from HCV infection (%) 28.5 ND N/A
ND, not determined; N/A, not applicable.
aThe majority of CHCV patients listed their likely source of infection as IDU; however, detailed data on historical and present injected behaviour were not 
collected. Within the CHCV group, the estimated median duration of infection was 31 years, with all individuals having been infected for a minimum of 6 
months prior to study recruitment.
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displaying absorbance readings ≥2 times the HC mean (Fig. 2a, Table S2) 
with 2 more showing above average binding to sE2 but below this cut- 
off value. Seven further individuals with significant responses against 
sE2 showed elevated reactivity against gt 1a lysate, but the absorbance 
attained did not reach the cut- off value. Only four samples showed sig-
nificant binding to sE2 alone. It should be noted that for the vast majority 
of assays the value of 2 times the HC mean was higher (therefore a more 
stringent cut- off) than HC mean + 2 times standard deviations.
3.6 | Ability­to­neutralize­HCVpp
Of those EU subject sera with significant binding to E1E2 by ELISA, 6 
(257, 306, 307, 315, 331- 1 and 458) showed ability to neutralize gt 1a 
HCVpp by 50% or more at a purified IgG concentration of 400 μg mL−1 
(Fig. 3a). For subjects 257, 306 and 307, this level of neutralization 
was achieved at a concentration of 200 μg mL−1, while IC50 value for 
the remaining samples was between 200 μg mL−1 and 400 μg mL−1 
(Fig. 3c).
Of those able to neutralize gt 1a HCVpp, 3 EU individuals (257, 
306 and 307) were also able to reduce infectivity of gt 3a HCVpp by 
F IGURE  2  IgG and IgM responses to soluble gt 1a E2 are evident 
in EU individuals. IgG (a) and IgM (b) absorbance to purified gt1a sE2 
protein was determined for EU and HC individuals using a modified 
ELISA protocol described in the Supplementary Methods. Statistical 
differences between the groups were calculated using the Wilcoxon 
rank sum test. **P<.01, *** P<.001
F IGURE  3 Neutralization of HCVpp by purified IgGs from EU. 
Virus pseudoparticle neutralization assays were performed using 
HCVpp bearing E1E2 derived from (a and c) gt 1a strain H77 or 
(b) gt 3 HCV. (a and b) Percentage reduction in HCVpp entry after 
incubation with 400 μg mL−1 test IgG is plotted as evidenced by 
luciferase reading at 72 hours compared to control. (c) Percentage 
reduction in HCVpp entry after incubation with reducing 
concentrations of IgG as shown. The 50% cut- off is shown as a 
dashed lined. All results represent the average of at least 3 separate 
technical replicates, with error bars representing the SEM
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50% or greater with one further gt 1a neutralizing subject reducing gt 
3a infectivity by 40% (EU 458) (Fig. 3b). Two further individuals (461, 
301) showed evidence of a weaker neutralization effect against both 
gt 1a and gt 3a HCVpp, consistently reducing infectivity by 40%.
3.7 | Competition­with­antibodies­to­
known­epitopes
IgG from EU individuals with evidence of neutralizing activity was 
tested in a competition assay with a small panel of well- characterized 
conformation- sensitive anti- E2 antibodies. Three of these (HC1, 
HC11 and CBH7) recognize amino acid residues/regions that are criti-
cal for the interaction of E2 to CD81, the host entry factor essential 
for virus entry into target cells13–16 (Table S1). Although chronically 
infected samples with neutralizing activity tended to compete with 
antibodies to these regions, we did not see any evidence of significant 
competition in the EU samples (Fig. 4). While there was evidence of 
binding to pure E2 in these samples at >2× control samples (Fig. 2a), 
it was considerably weaker than in individuals with chronic infection 
which bound to viral glycoproteins at >20 times the strength of HC 
samples (data not shown).
3.8 | Duration­of­antibody­detection­over­time
For 5 EU individuals, serial samples from time points separated by a 
period of at least 1 year were studied. Their E1E2 reactivity values 
relative to HC samples were consistent over the time periods studied, 
either remaining at HC levels or being consistently elevated (Fig. S1). 
In the one individual with significant E1E2 and neutralizing responses 
studied serially, these responses remained detectable over time but 
with a diminution in strength at later time points.
4  | DISCUSSION
Long- term injection drug users who recurrently, persistently and fre-
quently share injection equipment but who remain HCV antibody 
negative with undetectable HCV RNA represent an optimal cohort 
for advancing knowledge and understanding of mechanisms of natural 
protection from HCV infection. These individuals appear resistant to 
infection. Unlike HIV where resistance may be conferred by muta-
tions in host entry proteins, no such variants have been identified in 
HCV exposed uninfected cases.32–34 Therefore, it is likely that these 
subjects resist infection through immune- mediated mechanisms.
This study is the first to report evidence of humoral immunologi-
cal responses targeting the HCV envelope, potentially a key area for 
viral neutralization, in exposed uninfected individuals. While previous 
research has identified HCV- specific T- cell responses in EU individ-
uals, it remains unclear if those responses are able to protect from 
infection or, perhaps more likely, are merely a marker of viral exposure. 
This is supported by the fact that HCV- specific T- cell responses are 
generally weak and wane rapidly on the cessation of injection drug 
use.21,35 The presence of HCV envelope antibody responses provides 
further confirmation that this EU group has indeed been exposed to 
HCV infection, but whether the humoral response is robust enough to 
have a role in providing protection remains unanswered.
Anti- HCV humoral responses are not detected by diagnostic anti-
body assays in this cohort who by definition remain seronegative by 
conventional testing. However, it must be remembered that current 
commercial diagnostic assays do not detect anti- envelope antibod-
ies. We have identified anti- E1E2 IgG responses at levels significantly 
higher than controls in many EU cases with anti- E1E2 IgG binding at 
levels >2 times healthy controls in at least one assay observed in 20 
of the 42 EU cases. While such a cut- off is arbitrary and risks false- 
positive (and false- negative) results, all those with neutralizing activity 
show binding around this level supporting use of this cut- off.
Furthermore, IgGs from 6 of our cohort were able to reduce HCVpp 
entry into hepatocytes in vitro by 50% at IC50s ranging from 75 to 
400 mg mL−1 (equating to a serum dilution of 1:100–1:25) with other 
EU individuals demonstrating a weaker neutralizing response. These 
are comparable to the strength of neutralizing responses observed in 
spontaneous resolving patients during viral clearance.36 It is precisely 
this group of individuals that should be targeted in efforts to identify 
protective E1E2 epitopes for vaccine development.
Primate studies using HCV gt 1a envelope proteins as a vaccine 
immunogen have shown that neutralizing antibodies were raised in 
the majority of animals immunized on 2 occasions. These were able 
to prevent de novo infection and had some activity against strains of 
virus from different genotypes.37 In our cohort, in addition to serving 
as a marker of viral exposure, the presence of anti- envelope antibodies 
suggests one possible mechanism by which these subjects may have 
resisted infection. This is further supported by the in vitro evidence for 
viral neutralization with IgGs from a subset of individuals significantly 
reducing cellular entry by HCVpp.
In those who resolve acute infection, detectable neutralizing anti-
body responses are seen to reduce over a period of months to years 
F IGURE  4 EU IgG fails to compete with conformational 
antibodies to known epitopes on gt 1a E2. IgGs from individuals 
with neutralizing ability in the HCV pp system were selected for 
testing by competition ELISA to determine competitive binding with 
monoclonal antibodies to known conformational epitopes on E2 
(Table S1). Samples from chronically infected individuals (CHCV) with 
known neutralizing activity were also included as positive controls. 
Percentage reduction in absorbance of the monoclonal antibodies 
was calculated and plotted. Significant competition would be 
expected at a level of 50% inhibition
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following viral clearance although they may be restored in subsequent 
episodes of infection to aid more rapid viral control.12 The presence of 
potentially protective humoral responses in our cohort is seen most 
strikingly in cases with the greatest likelihood and frequency of HCV 
exposure. One individual in our cohort (331) showed the persistence 
of antibody responses over a period of a year. It remains to be deter-
mined if anti- envelope antibody responses need ongoing priming by 
exposure to HCV to be sustained or whether the responses demon-
strated could provide ongoing protection on cessation of IDU.
In order to establish whether there was evidence of recent expo-
sure to HCV envelope proteins, we looked for the evidence of IgM 
response to E2. While anti- HCV IgM persists in chronic infection, it 
wanes with viral clearance, with levels declining 8 weeks following 
exposure.38,39 The elevated levels of anti- E2 IgM observed in our EU 
subjects likely reflect an immune response to ongoing intermittent 
exposure to envelope proteins as might be expected through high- risk 
injecting practices. The strength of these responses was equivalent 
to those seen in chronically infected individuals, and the precise role 
of IgM in resisting infection in the EU cohort warrants further study.
While we have been able to show a neutralizing effect of EU IgG, 
the regions of the viral glycoprotein targeted by these antibodies 
have yet to be defined. The absence of competition with antibodies 
targeting known E2 epitopes raises the possibility that novel epi-
topes are involved. However, as avidity of binding increases with the 
duration of infection,40 it is also conceivable that the EU antibody 
responses are directed at CD81 binding regions in E2 but do not bind 
with sufficient avidity to avoid being ‘competed off’ by the confor-
mational antibodies derived from chronically infected individuals. It 
is also possible that these individuals, in common with most acutely 
infected cases, develop antibodies which predominantly target the 
Highly Variable Region- 1 region of the E2 protein or regions of E1 
essential for entry. An alternative explanation may be that due to 
high levels of diversity in E2 amino acid sequences, these individu-
als may raise antibodies to a local E2 sequence which only provides 
weak cross- reactivity with the H77 sequence at CD81 binding epi-
topes, and future work should aim to explore the breadth of E1E2 
reactivity within these individuals.
In conclusion, this is the first report of HCV envelope- specific 
humoral immune responses in a cohort of exposed uninfected injec-
tion drug users who remain HCV PCR and EIA negative despite 
repeated risk of exposure. In addition to adaptive humoral immune 
responses to envelope proteins, some individuals produce neutraliz-
ing anti- envelope antibodies which may contribute to host immunity. 
These neutralizing antibodies do not appear to compete with com-
monly targeted CD81 binding sites and may therefore recognize nov-
el epitopes. Our data complement previous reports of HCV- specific 
T- cell responses9,26 and upregulated innate immune responses in 
exposed uninfected cases.25 Together, these studies provide robust 
evidence that such individuals have been exposed to HCV, but are 
resistant to developing established infection. Whether any one of 
these responses is central to resisting infection, or whether a combi-
nation of upregulated innate immunity together with adaptive T- and 
B- cell responses is needed is not yet known. Further study of the 
antibody responses present in EU individuals will enhance our under-
standing of the role of antibodies in HCV infection and inform future 
preventative vaccine design.
ACKNOWLEDGEMENTS­AND­DISCLOSURES
We thank all those who kindly provided blood samples for study, 
and the community drug services who helped us identify and recruit 
exposed uninfected cases. We thank Francois- Loıc Cosset and 
Jonathan Ball for the provision of reagents; and Ania Owsianka, Sarah 
Cole and Vanessa Cowton for their valuable advice and help with 
experiments. We also thank Medical Research Council, UK (Grant 
Reference MC_UU_12014/2 and Clinical Research Fellowship Grant 
No: G0801822) and Plymouth Hospitals NHS Trust, South West Liver 
Unit for funding this study.
STATEMENT­OF­INTERESTS
The authors report no conflict of interests relevant to this manuscript. 
No external assistance was sought in the writing of this manuscript.
ABBREVIATIONS
CHCV, chronically HCV-infected Cohort; E1E2, envelope 
 glycoproteins 1 and 2; E2, envelope glycoprotein E2; EIA, enzyme 
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